24.90
-1.52 (-5.75%)
| Previous Close | 26.42 |
| Open | 26.82 |
| Volume | 284,205 |
| Avg. Volume (3M) | 635,808 |
| Market Cap | 1,895,629,440 |
| Price / Sales | 2.61 |
| Price / Book | 3.75 |
| 52 Weeks Range | |
| Earnings Date | 28 Mar 2025 |
| Operating Margin (TTM) | -8,344.08% |
| Diluted EPS (TTM) | -15.87 |
| Quarterly Revenue Growth (YOY) | 45,500.00% |
| Total Debt/Equity (MRQ) | 0.03% |
| Current Ratio (MRQ) | 35.30 |
| Operating Cash Flow (TTM) | -78.71 M |
| Levered Free Cash Flow (TTM) | -59.08 M |
| Return on Assets (TTM) | -15.02% |
| Return on Equity (TTM) | -19.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CG Oncology, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.28% |
| % Held by Institutions | 100.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Dec 2024 | 2,221,474 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (HC Wainwright & Co., 201.21%) | Buy |
| Median | 65.00 (161.04%) | |
| Low | 55.00 (Morgan Stanley, 120.88%) | Buy |
| Average | 65.00 (161.04%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 25.81 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Mar 2025 | 75.00 (201.20%) | Buy | 24.90 |
| 25 Mar 2025 | 75.00 (201.20%) | Buy | 27.54 | |
| Morgan Stanley | 07 Mar 2025 | 55.00 (120.88%) | Buy | 26.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 31 Mar 2025 | Announcement | CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates |
| 28 Mar 2025 | Announcement | CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates |
| 24 Mar 2025 | Announcement | Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy |
| 12 Mar 2025 | Announcement | CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates |
| 26 Feb 2025 | Announcement | CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |